dual glp 1 and gip receptor agonist examples The glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Injectable GLP-1 receptor agonists currently
Description
Its dosage is escalated every 4 weeks
When the body undergoes rapid fat loss, it interprets the change as a stress signal
Others may have protective genetic variants that already support healthy lipid profiles, meaning cholesterol gains from treatment are more modest but still meaningful
The two medicines act differently to manage blood sugar
Funding No funding
